Abstract:
Methods and compositions are provided for the direct catalytic asymmetric aldol reaction of aldehydes with donor molecules selected from ketones and nitroalkyl compounds. The reactions employ as catalyst a Group 2A or Group 2B metal complex of a ligand of formula (I), as defined further herein.
Abstract:
La presente invención se refiere a un procedimiento de síntesis de azetidina basado en reacciones de escisión radicalarias, que es más sencillo y directo que los métodos utilizados habitualmente. En dicho procedimiento se hace reaccionar un compuesto que contiene un alquilo C 2 sustituido o sin sustituir, con un nucleófilo que contiene un grupo -CH=CH-Z, donde Z puede ser arílo o heteroarilo.
Abstract:
The invention relates to new substituted triazinones of the general formula (I), in which n, Q, R , R , R , R and R have the meanings given in the description, to methods for producing same and to their use as herbicides.
Abstract:
One aspect of the present invention relates to novel ligands for transition metals. A second aspect of the present invention relates to the use of catalysts comprising these ligands in transition metal-catalyzed carbon-heteroatom and carbon-carbon bond-forming reactions. The subject processes provide improvements in many features of the transition metal-catalyzed reactions, including the range of suitable substrates, reaction conditions, and efficiency.
Abstract:
Compuesto de formula general (I)1 o cualquiera de sus sales, para su uso como composición farmacéutica para el tratamiento de enfermedades infecciosas, mas particularmente para el tratamiento de enfermedades causadas por Helicobacter . R1 es un átomo de H, X o un radical CX m H 3-m ; X representa un halógeno seleccionado de entre F, Cl, Br o I, y pueden ser igual o diferente, m toma valores de entre 1 a 3; R 2 es un grupo NO 2 , COOR' o SO 3 R'; R' representa un átomo de hidrógeno (H) o un grupo C 1 - C 6 alquilo; y n de entre 1 a 5.
Abstract translation:本发明涉及通式(I)化合物或其盐,用作治疗感染性疾病的药物组合物,特别是用于治疗由幽门螺杆菌引起的疾病。 R 1是H原子,X原子或C 3 H 3 H 3 - 基团,其中每个X可以相同或不同,并且是选自F,Cl ,Br或I,m是1和3之间的值; R 2是NO 2 CO 2基团,COOR'基团或SO 3 R'基团; R'是氢(H)原子或C 1 -C 6烷基; n为1〜5之间的值。
Abstract:
One aspect of the present invention relates to novel ligands for transition metals. A second aspect of the present invention relates to the use of catalysts comprising these ligands in transition metal-catalyzed carbon-heteroatom and carbon-carbon bond-forming reactions. The subject processes provide improvements in many features of the transition metal-catalyzed reactions, including the range of suitable substrates, reaction conditions, and efficiency.
Abstract:
At least one functional group selected between nitro and carboxyl groups can be introduced into a substrate by bringing the substrate into contact with at least one reactant selected from among (i) nitrogen oxides and (ii) carbon monoxide/oxygen mixtures in the presence of an imide compound represented by general formula (1), wherein R and R are each hydrogen, halogeno, alkyl, aryl or cycloalkyl, or alternatively they may be united to form a double bond or an aromatic or nonaromatic ring; W is O or OH; and n is 1 to 3, (e.g., N-hydroxy-phthalimide). The nitrogen oxides include compounds for the general formula: NxOy (such as N2O3 and NO2), and the substrate includes compounds bearing methyne carbon atoms, such as adamantane, and aromatic compounds having a methyl or methylene group at the position adjacent to the aromatic ring. Such a process enables efficient nitration or carboxylation even under relatively mild conditions.
Abstract translation:通过使底物与至少一种选自(i)氮氧化物和(ii)一氧化碳/氧混合物的反应物接触,在硝基和羧基之间选择的至少一个官能团可以引入基底 由通式(1)表示的酰亚胺化合物,其中R 1和R 2各自为氢,卤代,烷基,芳基或环烷基,或者它们可以一起形成双键或芳族或非芳族环; W是O或OH; n为1〜3(例如,N-羟基邻苯二甲酰亚胺)。 氮氧化物包括以下通式的化合物:N x O y(例如N 2 O 3和NO 2),并且底物包括具有甲炔碳原子的化合物,例如金刚烷,以及在与芳环相邻的位置具有甲基或亚甲基的芳族化合物 。 这种方法即使在相对温和的条件下也能有效地硝化或羧化。
Abstract:
The invention relates to a compound of general formula (I) or a salt thereof, for use as a pharmaceutical composition for treating infectious diseases, especially for treating diseases caused by Helicobacter. R1 is an H atom, an X atom or a CXmH3-m radical wherein each X can be the same or different and is a halogen selected from F, Cl, Br or I, and m is a value between 1 and 3; R2 is an NO2 group, a COOR' group or an SO3R' group; R' is a hydrogen (H) atom or a C1- C6 alkyl group; and n is a value between 1 and 5.
Abstract:
Conjugated nitro alkene compounds hamper or prevent proliferation of cancer cells in cell culture and in cancer patients, which can result in a decrease in tumor size and/or disappearance of the cancer. The compounds may act by interference with cancer cell biochemistry, in which isoprenoid groups such as farnesyl and geranylgeranyl become bonded to various oncogenic proteins such as Ras, RhoA, RhoB, or some other growth-related cellular protein(s).